VAXX · Vaxxinity, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|
| Revenue | - | $0 | $557.0K |
| Cost of Revenue | - | $0 | $52.0K |
| Gross Profit | - | $0 | $505.0K |
| R&D | $35.90M | $47.63M | $20.57M |
| SG&A | $22.39M | $28.35M | $12.22M |
| Total Operating Expenses | $58.28M | $75.98M | $32.79M |
| D&A | $2.23M | $1.68M | $717.0K |
| Operating Income | ($58.28M) | ($75.98M) | ($32.28M) |
| Interest Expense | $696.0K | $514.0K | $1.18M |
| Income Tax | - | $0 | $0 |
| Net Income | ($56.93M) | ($75.22M) | ($39.96M) |
| EPS - Basic | ($0.45) | ($1.79) | - |
| EPS - Diluted | ($0.45) | ($1.79) | - |
Balance Sheet
| Line item | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|
| Cash & Equivalents | $4.93M | $33.48M | $144.88M |
| Accounts Receivable | - | - | $0 |
| Inventory | - | - | - |
| Accounts Payable | - | $5.29M | $3.19M |
| Current Assets | $33.23M | $93.89M | $154.13M |
| Total Assets | $44.31M | $106.40M | $166.67M |
| Current Liabilities | $17.61M | $30.94M | $27.49M |
| Long-term Debt | - | - | - |
| Total Liabilities | $30.90M | $44.22M | $38.05M |
| Stockholders' Equity | $13.41M | $62.18M | $128.62M |
| Retained Earnings | ($361.64M) | ($304.70M) | ($229.48M) |
Cash Flow
| Line item | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|
| Operating Cash Flow | ($57.24M) | ($55.93M) | ($33.91M) |
| Investing Cash Flow | $28.84M | ($54.39M) | ($1.48M) |
| Financing Cash Flow | ($1.14M) | ($167.0K) | $196.17M |
| CapEx | $803.0K | $1.87M | $1.48M |
| Free Cash Flow | ($58.04M) | ($57.79M) | ($35.39M) |
Ratios
| Metric | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|
| Profitability | |||
| Gross margin | - | - | 90.7% |
| Operating margin | - | - | -5795.7% |
| EBITDA margin | - | - | -5667.0% |
| Net margin | - | - | -7173.6% |
| Free cash flow margin | - | - | -6353.1% |
| FCF / Net income | 1.02 | 0.77 | 0.89 |
| R&D / Revenue | - | - | 3693.0% |
| SG&A / Revenue | - | - | 2193.4% |
| Effective tax rate | - | - | - |
| Return on assets | -128.5% | -70.7% | -24.0% |
| Return on equity | -424.6% | -121.0% | -31.1% |
| Return on invested capital | - | - | - |
| Liquidity | |||
| Current ratio | 1.89 | 3.03 | 5.61 |
| Quick ratio | 1.89 | 3.03 | 5.61 |
| Cash ratio | 0.28 | 1.08 | 5.27 |
| Leverage | |||
| Debt / Equity | - | - | - |
| Debt / Assets | - | - | - |
| Debt / EBITDA | - | - | - |
| Interest coverage | -83.7x | -147.8x | -27.3x |
| Equity multiplier | 3.30 | 1.71 | 1.30 |
| Liabilities / Assets | 0.70 | 0.42 | 0.23 |
| Efficiency | |||
| Asset turnover | - | 0.00 | 0.00 |
| Inventory turnover | - | - | - |
| Days sales outstanding | - | - | 0d |
| Days inventory outstanding | - | - | - |
| Days payable outstanding | - | - | 22405d |
| Cash conversion cycle | - | - | - |
| Valuation | |||
| P / E | - | - | - |
| P / B | 8.0x | 1.7x | - |
| P / S | - | - | - |
| EV / EBITDA | - | - | - |
| Growth | |||
| Revenue growth (YoY) | - | -100.0% | - |
| Revenue CAGR (3y) | - | - | - |
| Revenue CAGR (5y) | - | - | - |
| Gross profit growth (YoY) | - | - | - |
| Operating income growth (YoY) | 23.3% | -135.4% | - |
| Net income growth (YoY) | 24.3% | -88.3% | - |
| EPS growth (YoY) | 74.9% | - | - |
| EPS CAGR (3y) | - | - | - |
| EPS CAGR (5y) | - | - | - |
| FCF growth (YoY) | -0.4% | -63.3% | - |
| FCF CAGR (5y) | - | - | - |
| Book value growth (YoY) | -78.4% | -51.7% | - |
Stability scores
Piotroski F-score
FY 2023 · 9-point quality
0/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Vaxxinity against the 5 most active filers in the same SIC group.